CAP Issue Brief: Gene Patents
CAP has long opposed the issuing of gene patents and is a co-plaintiff in the case Association of Molecular Pathology et al, vs Myriad Genetics, Inc., which the court decided June 13, 2013.
Audio Conference This Week on Gene Patent Decision
Join CAP this Wednesday, June 19, for a one-hour audio conference on the Supreme Court Gene Patent decision.
Statline Special Alert
CAP Hails Supreme Court Decision on Gene Patents
Genomic medicine achieved a major victory today as the Supreme Court invalidated the patents held by Myriad Genetics on the BRCA1 and BRCA2 genes, on the grounds that human genes are products of nature and therefore ineligible to be patented.
CAP has long opposed the issuing of gene patents and is a co-plaintiff in the case Association of Molecular Pathology et al, vs Myriad Genetics, Inc., which the court decided today. Read more.
Join us for CAPconnect’s next live chat Thursday, June 20 at 11am EST. Dr. Jonathan L. Myles, MD, FCAP, Chair of CAP’s Economic Affairs Committee, will lead this chat, which will focus on future opportunities—as well as reimbursement challenges—in In Vivo Microscopy.
Ronald Bardawil, MD, FCAP
We, as pathologists, have an image problem. We are not visible enough. The value that we provide as physicians frequently escapes other clinicians and patients, many of whom only see our names on bills but may not realize that there is a pathologist, a diagnostic expert behind that patient care.
Hepatopathology: Update on HCV in the Era of Genomic Medicine and Direct Antiviral Therapy.
Jonathan L. Myles, M.D., Chair of CAP’s Economic Affairs Committee has requested a meeting with Aetna’s head of regional network operations.
How labs are taming test utilization
It might be a legacy of the economic downturn. Perhaps it is the prospect of increased capitation under health care reform.
Now available - CAP TODAY’s online product guides.